Referencias

1. Jessup M. Aldosterone Blockade and Heart Failure. N Engl J Med. 2003; 348: 1380-1382.
    

2. Nabel EG. Cardiovascular disease. N Engl J Med 2003; 349: 60-72.
    

3. Weber KT. Aldosterone and spironolactone in heart failure. N Engl J Med 1999; 341:753-755
    

4. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265.
    

5. Lifton RP, Dluhy RG, Powers M, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992; 2: 66-74
    

6. Mitsuuchi Y, Kawamoto T, Naiki Y, et al. Congenitally defective aldosterone biosynthesis in humans: the involvement of point mutations of the P-450C18 gene (CYP11B2) in CMO II deficient patients. Biochem Biophys Res Commun 1992; 182: 974-979. Erratum, Biochem Biophys Res Commun 1992; 184: 1529-30
    

7. Luft FC. Present status of genetic mechanisms in hypertension. Med Clin N Am 2004; 88: 1-18.
    

8. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001; 293: 1107-1112.
    

9. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79: 407-414.
    

10. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet 1996; 12: 24-30.
     

11. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet 1996; 13: 183-188.
     

12. Struthers AD. Impact of aldosterone on vascular pathophysiology. Congest Heart Fail 2002; 8: 18-22.
     

13. Stier CT Jr, Rocha R, Chander PN. Effect of aldosterone and MR blockade on the brain and the kidney. Heart Fail Rev. 2005; 10(1): 53-62.
     

14. Frishman WH, Stier CT Jr. Aldosterone and aldosterone antagonism in systemic hypertension. Curr Hypertens Rep. 2004; 6 (3):195-200.
     

15. Takeda Y. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist. Hypertens Res. 2004; 27(11): 781-9.
     

16. Rajagopalan S, Pitt B. Aldosterone antagonists in the treatment of hypertension and target organ damage. Curr Hypertens Rep. 2001; 3(3): 240-8.
     

17. Callera GE, Montezano AC, Yogi A, Tostes RC, He Y, Schiffrin EL, Touyz RM. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension. 2005; 46(4): 1032-8.
     

18. Brown NJ.. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens. 2005; 14(3): 235-41.
     

19. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 2001; 28(10): 783-91.
     

20. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 2003; 16(1): 80-6.
     

21. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001; 345: 1689-1697.
     

22. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure. Circulation 2002; 105: 2099-2106.
     

23. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
     

24. Conlin PR. Interactions of high salt intake and the response of the cardiovascular system to aldosterone. Cardiol Rev. 2005; 13(3): 118-24.
     

25. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-2113.
     

26. Liew D, Krum H. Aldosterone receptor antagonists for hypertension: what do they offer? Drugs 2003; 63(19): 1963-72.
     

27. Sierra C, Ruilope LM. Role of the selective aldosterone receptor blockers in arterial hypertension. J Renin Angiotensin Aldosterone Syst. 2004; 5(1): 23-5.
     

28. Ambroisine ML, Milliez P, Nehme J, Pasquier AL, De Angelis N, Mansier P, Swynghedauw B, Delcayre C. Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. Diabetes Metab. 2004; 30(4): 311-8.
     

29. Reyes AJ, Leary WP, Crippa G, Maranhao MF, Hernández Hernández R. The aldosterone antagonist and facultative diuretic eplerenone: a critical review. Eur J Intern Med. 2005; 16(1): 3-11.
     

30. Brennan BJ, Martin NE. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease. J Am Pharm Assoc (Wash DC). 2004; 44(5):604-10.
     

31. Gumieniak O, Williams GH. Mineralocorticoid receptor antagonists and hypertension: is there a rationale? Curr Hypertens Rep. 2004; 6(4): 279-87.